Chemistry:Alinidine
From HandWiki
Short description: Chemical compound
 | |
| Clinical data | |
|---|---|
| ATC code |
|
| Legal status | |
| Legal status |
|
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider |
|
| UNII | |
| ChEMBL | |
| Chemical and physical data | |
| Formula | C12H13Cl2N3 |
| Molar mass | 270.16 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
 N Y (what is this?) (verify) | |
Alinidine (ST567) is a negative chronotrope that was developed in the 1970s and 1980s. It causes bradycardia by inhibiting the pacemaker current by altering the maximal channel conductance and alter the voltage threshold.[1] The development of alinidine was halted because it was not sufficiently specific for its target. It also has a blocking effect on calcium channels and potassium channels. It also causes elongation of re-polarisation after an action potential.[2]
Alinidine did not improve outcomes among patients with acute myocardial infarction in a randomized controlled trial.[3]
References
- ↑ Snyders DJ, Van Bogaert P-P: Alinidine modifies the pacemaker current in sheep Purkinje fibers. Pflügers Arch 1987, 410:83-91
- ↑ Current Opinion in Pharmacology 2007, 7:208–213
- ↑ "Short-term effects of early intravenous treatment with a beta-adrenergic blocking agent or a specific bradycardiac agent in patients with acute myocardial infarction receiving thrombolytic therapy.". J Am Coll Cardiol 22 (2): 407–16. 1993. doi:10.1016/0735-1097(93)90044-2. PMID 8335810.
| Sympatholytics (antagonize α-adrenergic vasoconstriction) |
| ||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Other antagonists |
| ||||||||||||||||||||||||||
| |||||||||||||||||||||||||||
| Calcium |
| ||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Potassium |
| ||||||||||||||||||||||||
| Sodium |
| ||||||||||||||||||||||||
| Chloride |
| ||||||||||||||||||||||||
| Others |
| ||||||||||||||||||||||||
 | 0.00  (0 votes) |
